



Approach to sensitivity evaluation of SARS-CoV-2 antigen rapid diagnostic tests (Ag RDT)

C. Micha Nübling

COVID-19 IVDs



Regulation of IVDs in Europe: in transition...



IVD Directive (2000 – May 2022)

SARS-CoV-2 IVD = Annex III products: "low risk"



- Self-Certification of SARS-CoV-2 IVD by manufacturer, basic requirements
 - (exception: self-tests; Notified Body assessment of lay man study)

IVD Regulation (from May 2022)



- SARS-CoV-2 IVD = Class D, highest risk group
- Certification by Notified Body + EU Reference Laboratory
- Distribution of COVID-19 IVD under old rules possible until May 2025



Approach in Germany



MoH: <u>reimbursement</u> of SARS-CoV-2 Ag RDT by German health care system linked to "minimal quality criteria" (manufacturer)

- Sensitivity: >80%
 - >100 unselected PCR pos, <7 days after symptoms
- Specificity: >97%
 - >100 asymptomatic individuals w/o exposure risk
- Potential cross reactivity

combined with

Comparative sensitivity evaluation (PEI / RKI)



Standardized multi-center comparative evaluation (PEI, RKI)


- Evaluation Panel (n=50 members)
 - 50 pools, eluted from <500 pharyngeal swabs (PBS)
 - Some pools with small amount of VTM
 - Viral load range determined by PCR
 - CT 17 36 6 orders of magnitude
 - CT 25 ≈ 1 mio RNA copies / mL)
 - Cell culture: infectious virus still detectable from samples with CT<25
 - 500 µl pools kept frozen at -80°C
 - After thawing, use of 50 µl aliquots within max. 5 days
 - SARS-CoV-2 antigen stable at +4°C for one week





Testing

- Inclusion of pre-analytical steps
 - Incubation of test-specific swabs in 50µl pool aliquots
 - Elution as described in the IFU





Test interpretation

- Independant visual reading by two persons
 - discrepant results (=reactive / non-reactive) in favor of test interpreted as "pos"
- Test validity; control line reactive
- Documentation by blot reader and foto

Criteria

 >75% detection rate for panel members with high viral loads (CT<25)



Comparative Sensitivity Evaluation (since Nov 2020)

226 tests evaluated (October 2021)

Target antigen: 95,7% N

2,5% S

1,8% N + S

>75% detection rate for CT<25

■ 183 pass

81%

43 fail

19%




SARS-CoV-2 Ag RDT: State of Art



226 tests evaluated (October 2021)


183 pass



SARS-CoV-2 Ag RDT: State of Art



226 tests evaluated (October 2021) 43 fail



Publications



(1) Design and manufacture panel

Puyskens A, Krause E, Michel J, Nübling CM, Scheiblauer H, Bourquain D, Grossegesse M, Valusenko R, Corman VM, Drosten C, Zwirglmaier K, Wölfel R, Lange C, Kramer J, Friesen J, Ignatius R, Müller M, Schmidt-Chanasit J, Emmerich P, Schaade L, Nitsche A.

Establishment of a specimen panel for the decentralised technical evaluation of the sensitivity of 31 rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021. Eurosurveillance 2021 (accepted)

(2) Comparative evaluation

Scheiblauer H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirglmaier K, Lange C, Emmerich P, Müller M, Knauer O, Nübling CM.

Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV-2 antigen, Germany, September 2020 to April 2021. Eurosurveillance 2021 (accepted)



Comparative Sensitivity Evaluation of 226 products (Nov 2020-Oct 2021) using standardized panel of 50 members (CT 17 – CT 36)

- SARS-CoV-2 RDT with <u>broad continous sensitivity range</u> (0/50 43/50 pos)
- "state of the art"

"75% for CT<25"

- Pre-analytical steps critical
- Batch-to-batch consistency
- Same original products often provided under different names, traceability
- Comparative evaluation continued (panel version 3)



Comparative Sensitivity Evaluation of 226 products (Nov 2020-Oct 2021) using standardized panel of 50 members (CT 17 – CT 36)

- Potential bias, e.g. PBS as diluent?
 - Results of all assays follow analyte concentration
 - Pools directly in elution buffer (w/o swab) results in higher sensitivity (Puyskens et al)

- Biological assays best standardized by biological material
 - native SARS-CoV-2 from repiratory specimens
 - Cell culture supernatant: clumping (?)



Thank you for your attention !!

micha.nuebling@pei.de

